Cargando…
Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin
Anti-DNA cell-penetrating autoantibodies have been extensively studied in autoimmune but not in normal sera. We investigated herein the presence and properties of cell-penetrating antibodies (CPAbs) in intravenous immunoglobulin (IVIg), a blood product of pooled normal human IgG. IVIg cell penetrati...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673440/ https://www.ncbi.nlm.nih.gov/pubmed/26682050 http://dx.doi.org/10.1038/cti.2015.18 |
_version_ | 1782404739670999040 |
---|---|
author | Sali, Aggeliki D Karakasiliotis, Ioannis Evangelidou, Maria Avrameas, Stratis Lymberi, Peggy |
author_facet | Sali, Aggeliki D Karakasiliotis, Ioannis Evangelidou, Maria Avrameas, Stratis Lymberi, Peggy |
author_sort | Sali, Aggeliki D |
collection | PubMed |
description | Anti-DNA cell-penetrating autoantibodies have been extensively studied in autoimmune but not in normal sera. We investigated herein the presence and properties of cell-penetrating antibodies (CPAbs) in intravenous immunoglobulin (IVIg), a blood product of pooled normal human IgG. IVIg cell penetration was observed into various cell lines, as well as cells from several organs of mice injected intravenously with IVIg therapeutic dose. In all cell types examined in vitro and in vivo, intracellular IgG localized in the cytoplasm, in contrast to the nuclear accumulation of disease-related CPAbs. IVIg was found to rapidly enter cells via an energy-independent mode. The CPAb-fraction was isolated and found to be polyreactive to nuclear and cytoplasmic components; although it corresponded to ~2% of IVIg, it accounted for its inhibitory effect on splenocyte activation. Investigation of IVIg cell penetration capacity provides insight into its mechanisms of action and may account for some of its beneficial effects in numerous diseases. |
format | Online Article Text |
id | pubmed-4673440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46734402015-12-17 Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin Sali, Aggeliki D Karakasiliotis, Ioannis Evangelidou, Maria Avrameas, Stratis Lymberi, Peggy Clin Transl Immunology Original Article Anti-DNA cell-penetrating autoantibodies have been extensively studied in autoimmune but not in normal sera. We investigated herein the presence and properties of cell-penetrating antibodies (CPAbs) in intravenous immunoglobulin (IVIg), a blood product of pooled normal human IgG. IVIg cell penetration was observed into various cell lines, as well as cells from several organs of mice injected intravenously with IVIg therapeutic dose. In all cell types examined in vitro and in vivo, intracellular IgG localized in the cytoplasm, in contrast to the nuclear accumulation of disease-related CPAbs. IVIg was found to rapidly enter cells via an energy-independent mode. The CPAb-fraction was isolated and found to be polyreactive to nuclear and cytoplasmic components; although it corresponded to ~2% of IVIg, it accounted for its inhibitory effect on splenocyte activation. Investigation of IVIg cell penetration capacity provides insight into its mechanisms of action and may account for some of its beneficial effects in numerous diseases. Nature Publishing Group 2015-10-02 /pmc/articles/PMC4673440/ /pubmed/26682050 http://dx.doi.org/10.1038/cti.2015.18 Text en Copyright © 2015 Australasian Society for Immunology Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Article Sali, Aggeliki D Karakasiliotis, Ioannis Evangelidou, Maria Avrameas, Stratis Lymberi, Peggy Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
title | Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
title_full | Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
title_fullStr | Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
title_full_unstemmed | Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
title_short | Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
title_sort | immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673440/ https://www.ncbi.nlm.nih.gov/pubmed/26682050 http://dx.doi.org/10.1038/cti.2015.18 |
work_keys_str_mv | AT saliaggelikid immunologicalevidenceandregulatorypotentialforcellpenetratingantibodiesinintravenousimmunoglobulin AT karakasiliotisioannis immunologicalevidenceandregulatorypotentialforcellpenetratingantibodiesinintravenousimmunoglobulin AT evangelidoumaria immunologicalevidenceandregulatorypotentialforcellpenetratingantibodiesinintravenousimmunoglobulin AT avrameasstratis immunologicalevidenceandregulatorypotentialforcellpenetratingantibodiesinintravenousimmunoglobulin AT lymberipeggy immunologicalevidenceandregulatorypotentialforcellpenetratingantibodiesinintravenousimmunoglobulin |